Invesco V.I. Health Care Fund

Invesco V.I. Health Care Fund reported 89 holdings worth US$161M as of Jun 30, 2026 (Form N-PORT)

As of Jun 30, 2026 · Filed Aug 25, 2026

Invesco V.I. Health Care Fund reported 89 holdings worth US$161M as of Jun 30, 2026. Largest: Eli Lilly And Company, Johnson & Johnson and Unitedhealth Group Incorporated. Filed Aug 25, 2026 (Form N-PORT).

Holdings
89
Value as reported
US$161M

The filing in full

CompanySharesValue as reported% of portfolio
Eli Lilly And Company14,514US$17.4M10.8%
Johnson & Johnson39,684US$10.1M6.3%
Unitedhealth Group Incorporated23,507US$9.77M6.1%
Merck & Company, Inc.52,450US$6.74M4.2%
Argenx Se6,892US$6.39M4.0%
Abbvie Inc.25,391US$6.39M4.0%
Gilead Sciences, Inc.43,847US$5.54M3.4%
Astrazeneca Plc24,827US$4.71M2.9%
Brightspring Health Services, Inc.62,746US$4.38M2.7%
Welltower Inc.15,671US$3.56M2.2%
Cvs Health Corporation34,035US$3.52M2.2%
Cardinal Health, Inc.14,255US$3.39M2.1%
Vertex Pharmaceuticals Incorporated6,623US$3.29M2.0%
Royalty Pharma Plc57,339US$3.21M2.0%
Guardant Health, Inc.19,834US$2.98M1.9%
Axsome Therapeutics, Inc.11,411US$2.79M1.7%
Edwards Lifesciences Corporation28,490US$2.58M1.6%
Ucb S.a.7,580US$2.27M1.4%
Bridgebio Pharma, Inc.28,134US$2.1M1.3%
Ligand Pharmaceuticals Incorporated6,427US$2.03M1.3%
Sandoz Group Ltd22,014US$1.99M1.2%
Waters Corporation5,140US$1.93M1.2%
Ascendis Pharma A/s7,074US$1.89M1.2%
Natera, Inc.6,812US$1.85M1.2%
Revolution Medicines, Inc.9,137US$1.71M1.1%
Protagonist Therapeutics, Inc.13,525US$1.66M1.0%
United Therapeutics Corporation2,998US$1.62M1.0%
Intuitive Surgical, Inc.3,973US$1.58M0.98%
Halozyme Therapeutics, Inc.20,180US$1.58M0.98%
Iqvia Holdings, Inc.7,880US$1.52M0.95%
Madrigal Pharmaceuticals, Inc.2,753US$1.48M0.92%
Galderma Group Ag6,470US$1.47M0.92%
Medline Inc.34,369US$1.36M0.84%
West Pharmaceutical Services, Inc.3,646US$1.31M0.81%
Mettler-toledo International, Inc.1,020US$1.3M0.81%
Lonza Group Ag1,915US$1.29M0.80%
Quest Diagnostics Incorporated5,645US$1.2M0.74%
Alignment Healthcare, Inc.49,963US$1.19M0.74%
Charles River Laboratories International, Inc.5,131US$1.16M0.72%
Thermo Fisher Scientific Inc2,283US$1.14M0.71%
Ionis Pharmaceuticals, Inc.13,962US$1.11M0.69%
Idexx Laboratories, Inc.2,078US$1.09M0.68%
Insmed Incorporated9,751US$1.04M0.65%
Twist Bioscience Corporation9,702US$998K0.62%
Labcorp Holdings Inc.3,544US$992K0.62%
Cytokinetics, Incorporated11,172US$952K0.59%
Steris Plc (ireland)4,309US$907K0.56%
Globus Medical, Inc.11,395US$900K0.56%
Repligen Corporation6,148US$839K0.52%
Rhythm Pharmaceuticals, Inc.7,408US$823K0.51%
Tenet Healthcare Corporation4,134US$773K0.48%
Krystal Biotech, Inc.1,968US$731K0.46%
Praxis Precision Medicines, Inc.2,166US$725K0.45%
Encompass Health Corporation6,970US$705K0.44%
Hca Healthcare, Inc.1,777US$693K0.43%
Mirum Pharmaceuticals, Inc.5,850US$685K0.43%
Arrowhead Pharmaceuticals, Inc.7,737US$631K0.39%
Regeneron Pharmaceuticals, Inc.1,002US$625K0.39%
Medpace Holdings, Inc.1,130US$598K0.37%
Rapport Therapeutics, Inc.14,308US$596K0.37%
Mckesson Corporation785US$593K0.37%
Biolife Solutions, Inc.19,732US$557K0.35%
Lemaitre Vascular, Inc.5,730US$550K0.34%
Billiontoone, Inc.4,385US$526K0.33%
Radnet, Inc.7,870US$485K0.30%
Heartflow, Inc.15,766US$463K0.29%
Dianthus Therapeutics, Inc.4,361US$425K0.26%
Palvella Therapeutics, Inc.2,691US$411K0.26%
Tarsus Pharmaceuticals, Inc.6,525US$411K0.26%
Xenon Pharmaceuticals Inc.6,800US$410K0.26%
Glaukos Corporation2,922US$408K0.25%
Cogent Biosciences, Inc.9,662US$374K0.23%
Uniqure N.v.6,887US$317K0.20%
Centene Corporation4,932US$317K0.20%
Phathom Pharmaceuticals, Inc.24,059US$261K0.16%
Gmr Solutions Inc.15,649US$242K0.15%
Mineralys Therapeutics, Inc.7,305US$197K0.12%
Genedx Holdings Corp.0US$00.00%
Boston Scientific Corporation0US$00.00%
Irhythm Holdings, Inc.0US$00.00%
Cencora, Inc.0US$00.00%
Nuvalent, Inc.0US$00.00%
Bio-techne Corp0US$00.00%
Caris Life Sciences, Inc.0US$00.00%
Stryker Corporation0US$00.00%
Transmedics Group, Inc.0US$00.00%
Healthequity, Inc.0US$00.00%
Beone Medicines Ltd. Class A0US$00.00%
Alnylam Pharmaceuticals, Inc.0US$00.00%

Source

View original at SEC

Related